Project Studie ImmunoCobiVem

Basic data

Title:
Studie ImmunoCobiVem
Duration:
15/08/2016 to 31/12/2019
Abstract / short description:
Multizentrische, offene, randomisierte, klinische Prüfung der Phase II zur Bestimmung der Wirksamkeit und Sicherheit einer sequentiellen Therapie mit Cobimetinib plus Vemurafenib gefolgt von einer Immuntherapie mit dem PD-L1-Antikörper Atezolizumab zur Behandlung von Patienten mit inoperablem oder metastasiertem Melanom mit BRAFV600 Mutation

Involved staff

Managers

Department of Dermatology
Hospitals and clinical institutes, Faculty of Medicine

Contact persons

Department of Dermatology
Hospitals and clinical institutes, Faculty of Medicine
Tampouri, Ioanna
Department of Dermatology
Hospitals and clinical institutes, Faculty of Medicine
Department of Dermatology
Hospitals and clinical institutes, Faculty of Medicine
Spänkuch, Iris
Department of Dermatology
Hospitals and clinical institutes, Faculty of Medicine
Lomberg, Diana
Department of Dermatology
Hospitals and clinical institutes, Faculty of Medicine
Department of Dermatology
Hospitals and clinical institutes, Faculty of Medicine

Local organizational units

Department of Dermatology
Hospitals and clinical institutes
Faculty of Medicine

Funders

Duisburg, Nordrhein-Westfalen, Germany
Help

will be deleted permanently. This cannot be undone.